Keros Therapeutics (KROS) Receivables Refunds (2025)
Keros Therapeutics posted quarterly Receivables Refunds of $2.2 million for Q4 2025.
Keros Therapeutics (KROS) has 1 years of Receivables Refunds data on file, last reported at $2.2 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables Refunds changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (changed N/A YoY), and the FY2025 full-year result was $2.2 million, changed N/A from the prior year.
- Receivables Refunds for Q4 2025 stood at $2.2 million.
- Across five years, Receivables Refunds topped out at $2.2 million in Q4 2025 and bottomed at $2.2 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.25 Mn |